N/A N=20 Poor Sleep and Inflammation in HIV-Infected Adults
HIV-1-infection · Sleep Deprivation · Inflammation
Primary: Soluble CD14 — 1290; 1196 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation
Atrial Fibrillation
Primary: Pulmonary Vein Reconnection — 10; 10 Participants — p=<0.01
Phase 2 N=12 ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
Immunologic Deficiency Syndromes
Primary: Survival — 12 Participants
Phase 2 N=10 MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Severe Combined Immunodeficiency
Primary: Number of Participants With Adverse Events — 10; 9; 0; 10 participants
N/A N=32 Registry Study of Revcovi Treatment in Patients With ADA-SCID
Adenosine Deaminase Severe Combined Immunodeficiency
Primary: Number of Subjects Meeting the Toxicity Threshold for Deoxyadenosine Nucleotide (dAXP) Concentration at the Last Measurement — 6; 17; 4 Participants
N/A N=12 Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Coronary Artery Disease
Primary: Global Hyperemic Myocardial Blood Flow (MBF) — 3.1; 3.1 mL/min/gm — p=0.14
Phase 1 N=46 Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
Coronary Artery Disease
Primary: Difference in FFR Between IV Adenosine and IV Regadenoson — 0.84; 0.84 ratio (Pd/Pa)
Phase 4 N=201 Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
Percutaneous Coronary Intervention
Primary: Comparison Between Contrast Fractional Flow Reserves (cFFR) and Adenosine Fractional Flow Reserves (aFFR) — 0.8922 proportion of lesions with agreement
Phase 2 N=36 Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Adenosine Deaminase Deficiency · Severe Combined Immunodeficiencies (SCID)
Primary: Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) — 100; 100; 100; 100 percentage of participants
N/A N=259 Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)
Severe Hypoglycemia
Primary: Self-reported Severe Hypoglycemia — 99; 99; 19; 13 Participants — p=0.27
Phase 2 N=21 Oral Nitrite for Older Heart Failure Patients
Heart Failure
Primary: Skeletal Muscle Bioenergetics- Polymerase Chain Reaction (PCR) — 12.04; 11.91; 11.79; 11.76 Relative Expression
N/A N=30 Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
Type 2 Diabetes · Cardiovascular Disease
Primary: Peak Oxygen Consumption (VO2peak). — 1893; 1953; 1849; 1881 ml/min
Phase 1 N=185 TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Solid Tumor, Adult
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 6; 0; 0; 0 Participants
Phase 4 N=46 Cilostazol Augmentation Study in Dementia
Alzheimer's Dementia
Primary: Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method — 81.70; 80.40; 84.60; 81.33 Bq/Bq (no unit) — p=0.14
Phase 3 N=378 Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
Atrial Fibrillation · Persistent Common Pulmonary Vein
Primary: Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion — 92 participants